JP2731636B2 - 抗潰瘍剤、抗生物質の錯体又はキレート及びその製造方法 - Google Patents

抗潰瘍剤、抗生物質の錯体又はキレート及びその製造方法

Info

Publication number
JP2731636B2
JP2731636B2 JP3041832A JP4183291A JP2731636B2 JP 2731636 B2 JP2731636 B2 JP 2731636B2 JP 3041832 A JP3041832 A JP 3041832A JP 4183291 A JP4183291 A JP 4183291A JP 2731636 B2 JP2731636 B2 JP 2731636B2
Authority
JP
Japan
Prior art keywords
azithromycin
complex
chelate
gel
ulcer agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP3041832A
Other languages
English (en)
Japanese (ja)
Other versions
JPH06184186A (ja
Inventor
スロボダン・デイオキツク
ツラトコ・ヴアイトナー
ルボイエ・クルニエヴイツク
ネヴエンカ・ロポタル
リデイヤ・コカクニイ−バビツク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pliva Farmaceutika dd
Original Assignee
Pliva Farmaceutska Kemijska Prehrambena I Kozmeticka Industrija dd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva Farmaceutska Kemijska Prehrambena I Kozmeticka Industrija dd filed Critical Pliva Farmaceutska Kemijska Prehrambena I Kozmeticka Industrija dd
Publication of JPH06184186A publication Critical patent/JPH06184186A/ja
Application granted granted Critical
Publication of JP2731636B2 publication Critical patent/JP2731636B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP3041832A 1990-03-07 1991-03-07 抗潰瘍剤、抗生物質の錯体又はキレート及びその製造方法 Expired - Lifetime JP2731636B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
YU455/90 1990-03-07
YU45590A YU45590A (sh) 1990-03-07 1990-03-07 Novi kompleksi odnosno helati antibiotika s dvovalentnim i/ili trovalentnim metalima i postupci za njihovo dobijanje

Publications (2)

Publication Number Publication Date
JPH06184186A JPH06184186A (ja) 1994-07-05
JP2731636B2 true JP2731636B2 (ja) 1998-03-25

Family

ID=25550003

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3041832A Expired - Lifetime JP2731636B2 (ja) 1990-03-07 1991-03-07 抗潰瘍剤、抗生物質の錯体又はキレート及びその製造方法

Country Status (20)

Country Link
US (1) US5498699A (enExample)
EP (1) EP0445743B1 (enExample)
JP (1) JP2731636B2 (enExample)
CN (2) CN1041166C (enExample)
AT (1) ATE143266T1 (enExample)
BG (1) BG61230B1 (enExample)
CA (1) CA2037663C (enExample)
CZ (1) CZ280181B6 (enExample)
DE (1) DE69122282T2 (enExample)
DK (1) DK0445743T3 (enExample)
ES (1) ES2094763T3 (enExample)
GR (1) GR3021947T3 (enExample)
HR (1) HRP940256B1 (enExample)
HU (2) HU209455B (enExample)
PL (1) PL166279B1 (enExample)
RO (1) RO107660B1 (enExample)
RU (2) RU2039060C1 (enExample)
SI (1) SI9010455B (enExample)
SK (1) SK279278B6 (enExample)
YU (1) YU45590A (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2064634C (en) * 1991-04-04 1998-08-04 James V. Heck 9-deoxo-8a-aza-8a-homoerythromycin a derivatives modified at the 4"- and8a-positions
GB9120131D0 (en) * 1991-09-20 1991-11-06 Glaxo Group Ltd Medicaments
TW271400B (enExample) * 1992-07-30 1996-03-01 Pfizer
JPH10512877A (ja) * 1995-01-26 1998-12-08 ニコムド イメージング エイ／エス ビスマス化合物
GB9501560D0 (en) * 1995-01-26 1995-03-15 Nycomed Imaging As Contrast agents
US5900410A (en) * 1996-08-27 1999-05-04 Hartmann; John F. Monotherapy of peptic ulcers and gastritis
US6861411B1 (en) 1997-12-02 2005-03-01 Pfizer, Inc. Method of treating eye infections with azithromycin
US7056893B2 (en) 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
HRP20010301A2 (en) * 2001-04-27 2001-12-31 Pliva D D New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
EP1652851A1 (en) 2001-05-22 2006-05-03 Pfizer Products Inc. New crystal form of Azithromycin
KR20040032942A (ko) * 2001-08-21 2004-04-17 화이자 프로덕츠 인코포레이티드 호흡기 감염증을 치료하기 위한 일회분량의 아지트로마이신
RU2283116C2 (ru) * 2002-05-27 2006-09-10 Курский государственный медицинский университет Способ увеличения выживаемости изолированного кожного лоскута "на ножке" у животных с пониженным антиоксидантным фоном
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060046970A1 (en) * 2004-08-31 2006-03-02 Insite Vision Incorporated Topical otic compositions and methods of topical treatment of prevention of otic infections
JP2008518025A (ja) * 2004-10-25 2008-05-29 パラテック ファーマシューティカルズ インコーポレイテッド ４−アミノテトラサイクリンおよびその使用の方法
WO2008045507A2 (en) 2006-10-11 2008-04-17 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of bacillus anthracis infections
CN104892694A (zh) * 2015-05-24 2015-09-09 广西师范学院 蔗糖硫酸酯铜类化合物及其制作方法和用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862225A (en) * 1961-08-18 1975-01-21 Pfizer D-ring substituted tetracyclines
US3622627A (en) * 1967-09-13 1971-11-23 Pfizer 4-dedimethylaminatetracycline and 5a, 6-anhydro derivatives thereof
HU167946B (enExample) * 1973-04-16 1976-01-28
YU43006B (en) * 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
WO1986005981A1 (en) * 1985-04-18 1986-10-23 Borody Thomas J Treatment of non-ulcer dyspepsia with bismuth salts
DE3650504T2 (de) * 1985-06-13 1996-10-31 Marshall Barry James Verfahren und Zusammensetzungen zur Behandlung von gastrointestinalen Störungen
IT1200774B (it) * 1985-10-10 1989-01-27 Pierrel Spa Procedimento di sentisi dell'amikacina
YU44599B (en) * 1986-09-12 1990-10-31 Pliva Pharm & Chem Works Process for preparing complex of n-methyl-11-aza-10-deoxo-10-dihydroeritromicine a and 11-aza-10-deoxo-10-dihydroeritromicine a with metals
HU198913B (en) * 1987-09-03 1989-12-28 Pliva Pharm & Chem Works Process for producing 10-dihydro-10-deoxo-11-aza-erythronolide a-derivatives and pharmaceutical compositions containing them as active components
JP2733849B2 (ja) * 1987-10-12 1998-03-30 ボロディー，ソーマス・ユリウス 胃腸障害治療のための改良された方法
US5246708A (en) * 1987-10-28 1993-09-21 Pro-Neuron, Inc. Methods for promoting wound healing with deoxyribonucleosides
DE391005T1 (de) * 1989-04-03 1991-04-11 Ranbaxy Laboratories, Ltd., New Delhi Verfahren zur herstellung von alpha-6-deoxytetracyclinen.
US5348946A (en) * 1991-02-28 1994-09-20 Biochem Immunosystems, Inc. Heteroanthracycline antitumor analogs
MA28714B1 (fr) * 2005-12-15 2007-07-02 Green Technlology Sarl Une arabinogalactane proteine ayant la propriete d'absorber les graisses et le procede d'obtention de cette arabinogalactane proteine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ａｎｔｉｍｉｃｒｏｂｉａｌ Ａｇｅｎｔｓ ａｎｄ Ｃｈｅｍｏｔｈｅｒａｐｙ，３４，［１］，（１９９０），ｐ２５−２８
Ｊｏｕｒｎａｌ ｏｆ ＡｎｔｉｍｉｃｒｏｂｉａＬ Ｃｈｅｍｏｔｈｅｒａｐｙ，２２，（１９８８），ｐ６３１−６３６

Also Published As

Publication number Publication date
BG93995A (bg) 1993-12-24
CA2037663C (en) 1999-01-19
DE69122282T2 (de) 1997-04-24
SK279278B6 (sk) 1998-09-09
EP0445743A2 (en) 1991-09-11
JPH06184186A (ja) 1994-07-05
BG61230B1 (bg) 1997-03-31
EP0445743B1 (en) 1996-09-25
DE69122282D1 (de) 1996-10-31
RO107660B1 (ro) 1993-12-30
CN1054534A (zh) 1991-09-18
HU209455B (en) 1994-06-28
CN1051560C (zh) 2000-04-19
CN1041166C (zh) 1998-12-16
US5498699A (en) 1996-03-12
HUT56849A (en) 1991-10-28
YU45590A (sh) 1992-07-20
PL166279B1 (pl) 1995-04-28
RU2039061C1 (ru) 1995-07-09
HU211475A9 (en) 1995-11-28
HRP940256A2 (en) 1997-06-30
DK0445743T3 (enExample) 1997-02-17
CS9100587A2 (en) 1991-10-15
GR3021947T3 (en) 1997-03-31
SI9010455B (sl) 2000-04-30
CA2037663A1 (en) 1991-09-08
ATE143266T1 (de) 1996-10-15
CN1168891A (zh) 1997-12-31
HU910740D0 (en) 1991-09-30
SI9010455A (en) 1997-08-31
RU2039060C1 (ru) 1995-07-09
CZ280181B6 (cs) 1995-11-15
ES2094763T3 (es) 1997-02-01
HRP940256B1 (en) 1998-10-31
EP0445743A3 (en) 1992-10-07

Similar Documents

Publication Publication Date Title
JPH06184186A (ja) 抗潰瘍剤、抗生物質の錯体又はキレート及びその製造方法
DE69222950T2 (de) Darmlösliche oral verabreichbare arzneimittel welche säurelabile verbindungen enthalten
JPS6377895A (ja) １１−アザ−１０−デオキソ−１０−ジヒドロエリスロマイシンａ又はそのｎ−メチル誘導体の金属錯塩及びそれらの製造法
CN1128999A (zh) 杂环化合物
JPS604189B2 (ja) 抗菌剤およびその製法
EP0923932B1 (en) Composition containing antitumor agent
KR860000450B1 (ko) α-6-데옥씨-5-하이드록씨 테트라 싸이클린과 소듐 테트라메타포스 페이트의 수용성 복합체의 제조방법
JPS6272616A (ja) 抗菌剤
JPS60152462A (ja) インド−ル酢酸アミド誘導体の製造方法
JP3813644B2 (ja) ビスマス錯体およびそれを含有する抗菌剤
KR100344099B1 (ko) 신규한비페닐디카르복실산유도체와이의제조방법
CA2247329C (en) Composition containing antitumor agent
JPH01121273A (ja) ベンズイミダゾール誘導体の多形体
JPH0153668B2 (enExample)
JPH10218888A (ja) 有機ビスマス誘導体
WO1990015811A1 (fr) Spicamycine x et son utilisation
JPH01121272A (ja) ベンズイミダゾール誘導体の多形体
WO2007049296A2 (en) Amorphous form of telithromycin
HU181455B (hu) Eljárás maltobionsav fémkomplexeinek előállítására